Related Experiment Video

Updated: Jun 5, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Polymorphisms in MMP-9 and TIMP-2 in Chinese patients with varicose veins

Hong-mei Xu1, Yun Zhao, Xiang-man Zhang

  • 1Department of Forensic Medicine, Shanghai Medical College, Fudan University, Shanghai, China.

The Journal of Surgical Research
|January 4, 2011
PubMed

Insights

Genetic variations in MMP-9 and TIMP-2 promoters are linked to varicose veins (VVs) risk in the Chinese population. This study identifies potential genetic factors contributing to VV development.

Area of Science:

  • Genetics
  • Vascular Biology
  • Molecular Medicine

Background:

  • Varicose veins (VVs) are prevalent vascular diseases characterized by vein dilation and tortuosity.
  • The underlying pathophysiology and molecular mechanisms of VVs remain largely unknown.
  • Genetic predisposition to VVs is recognized, but specific genetic variants have not been identified.

Purpose of the Study:

  • To investigate the association between promoter polymorphisms in Matrix Metalloproteinase-9 (MMP-9) and Tissue Inhibitor of Metalloproteinase-2 (TIMP-2) and the risk of developing VVs.
  • To explore the role of these genetic variants in the Chinese population.

Main Methods:

  • Genotyping of MMP-9 (-1562C/T) and TIMP-2 (-418G/C) promoter polymorphisms using Polymerase Chain Reaction and Restriction Fragment Length Polymorphism (PCR-RFLP).
  • Analysis involved 60 patients diagnosed with VVs and 60 healthy control individuals.
  • Sequencing of purified PCR products was performed for confirmation.

Main Results:

  • A statistically significant correlation was observed between the MMP-9 -1562C/T polymorphism and the presence of VVs.
  • The TIMP-2 gene polymorphism -418G/C also demonstrated a significant association with VVs.

Conclusions:

  • Promoter region polymorphisms in MMP-9 and TIMP-2 are associated with an increased risk of varicose veins in the Chinese population.
  • These findings suggest a potential genetic contribution of MMP-9 and TIMP-2 variants to the development of VVs.
Abstract

Related Concept Videos

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Role of Matrix Metalloproteases in Degradation of ECM01:23

Role of Matrix Metalloproteases in Degradation of ECM

Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult body.
A...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...